-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, chimeric antigen receptor T cells (CAR-T) have been effective in treating lymphoma and leukemia.
A large number of clinical trials and studies have promoted the rapid development of CAR-T cell therapy.
However, the approved CAR-T cell drugs in China are still In the blank period
.
On June 22, 2021, the National Medical Products Administration (NMPA) officially approved Fosun Kate’s CD19 autologous CAR-T cell therapy drug Yikaida® (Akilunza injection) to fill the domestic long-term CAR-T drug Blank, as the first CAR-T cell therapy approved for marketing in China, it is used to treat adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) after receiving second-line or above systemic treatment.
/R LBCL patients bring new hope for long-term survival
.
Domestic and foreign research data show that the best overall response rate of Yikaida® is 79.
2%, the objective response rate is 83%, the complete response rate is 58%, and the 4-year overall survival rate is 44%, which significantly improves the overall survival of patients.
Quality of life
.
From 20:00-21:50 on September 18th, we will invite experts and scholars in the field of hematology: Professor Li Jianyong from Jiangsu Provincial People's Hospital to serve as the chairperson; invite Prof.
Lin Yi from Mayo Clinic Rochester District to share foreign practical experience, Jiangsu Province Professor Xu Wei from the People’s Hospital conducted an interpretation of the real-world evidence for CAR-T treatment of lymphoma; at the same time, Professor Wang Li, Professor Cao Lei, Professor Liang Jinhua, Professor Miao Yi, Professor Peng Chen, Professor Shen Haorui, and Wang Sanmei were specially invited Professors, Professor Wu Jiazhu, Professor Wu Wei, Professor Xia Yi, Professor Yin Hua, and Professor Zhao Xiaoli served as panellists, bringing us an academic feast together
.
A large number of clinical trials and studies have promoted the rapid development of CAR-T cell therapy.
However, the approved CAR-T cell drugs in China are still In the blank period
.
On June 22, 2021, the National Medical Products Administration (NMPA) officially approved Fosun Kate’s CD19 autologous CAR-T cell therapy drug Yikaida® (Akilunza injection) to fill the domestic long-term CAR-T drug Blank, as the first CAR-T cell therapy approved for marketing in China, it is used to treat adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) after receiving second-line or above systemic treatment.
/R LBCL patients bring new hope for long-term survival
.
Domestic and foreign research data show that the best overall response rate of Yikaida® is 79.
2%, the objective response rate is 83%, the complete response rate is 58%, and the 4-year overall survival rate is 44%, which significantly improves the overall survival of patients.
Quality of life
.
From 20:00-21:50 on September 18th, we will invite experts and scholars in the field of hematology: Professor Li Jianyong from Jiangsu Provincial People's Hospital to serve as the chairperson; invite Prof.
Lin Yi from Mayo Clinic Rochester District to share foreign practical experience, Jiangsu Province Professor Xu Wei from the People’s Hospital conducted an interpretation of the real-world evidence for CAR-T treatment of lymphoma; at the same time, Professor Wang Li, Professor Cao Lei, Professor Liang Jinhua, Professor Miao Yi, Professor Peng Chen, Professor Shen Haorui, and Wang Sanmei were specially invited Professors, Professor Wu Jiazhu, Professor Wu Wei, Professor Xia Yi, Professor Yin Hua, and Professor Zhao Xiaoli served as panellists, bringing us an academic feast together
.
